Celgene Corporation Announces Financial Outlook and Preliminary 2012 Results
Published: Jan 07, 2013
Celgene Corporation (NASDAQ: CELG) provided its financial outlook for 2013 at the JPMorgan 31st Annual Healthcare Conference. In 2013, total net product sales are expected to be approximately $6.0 billion, an 11.4% year-over-year increase. REVLIMID net sales are expected to be in the range of $4.1 billion to $4.2 billion, including approximately $90 million of negative year-over-year foreign exchange impact. Assuming constant foreign exchange, REVLIMID growth would be 11 to 14 percent. Adjusted diluted earnings per share (EPS) is expected in the range of $5.50 to $5.60, a 12 to 14 percent year-over-year increase. Based on U.S. Generally Accepted Accounting Principles (GAAP), diluted EPS is expected in the range of $4.67 to $4.79.